I thank Deputy Flaherty for raising this issue and for his comprehensive explanation. It is not a condition I am overly familiar with. I will first provide some background for our colleagues and then address his question. This medicine is used to treat polyneuropathy - nerve damage - caused by hATTR. The European Medicines Agency, EMA, granted marketing authorisation for this product in September 2022. As hATTR amyloidosis is a rare disease, the EMA has also designated this an orphan medicine. The company marketing…